What is Medpace?
Headquartered in Cincinnati, Ohio, Medpace operates as a premier global clinical research organization (CRO). The company provides an end-to-end suite of development services, supporting clients from initial early-stage research through the rigorous demands of late-stage clinical trials and final regulatory approval. Its business model is distinguished by a scientifically driven approach, which allows for greater precision in managing the development lifecycles of medical therapies and devices. By acting as an independent partner, Medpace facilitates the acceleration of life-saving innovations, ensuring that complex clinical data is managed with the highest standards of integrity and regulatory compliance.
How much funding has Medpace raised?
Medpace has raised a total of $161M across 1 funding round:
Stock Offering
$161M
Stock Issuance/Offering (2016): $161M, investors not publicly disclosed
Key Investors in Medpace
Undisclosed Institutional Investor
An institutional entity providing capital to support the long-term growth and operational scaling of established clinical research organizations.
Undisclosed Private Equity Partner
A private equity firm focused on backing high-growth life sciences companies with significant market share and proven operational models.
Undisclosed Strategic Backer
A strategic investor specializing in the healthcare and pharmaceutical services sector, providing capital to facilitate global expansion.
What's next for Medpace?
With the infusion of this major enterprise-level funding, Medpace is well-positioned to expand its operational footprint and enhance its technological capabilities in clinical trial management. The strategic allocation of these resources will likely focus on deepening its expertise in specialized therapeutic areas and scaling its global infrastructure to meet the increasing demand for outsourced clinical development. As the pharmaceutical industry continues to prioritize efficiency and speed-to-market, Medpace is poised to leverage its current financial backing to solidify its competitive advantage, potentially through the integration of advanced data analytics and expanded regulatory support services to further streamline the path from laboratory to patient.
See full Medpace company page
